论文部分内容阅读
目的:观察磷酸西格列汀联合阿卡波糖治疗老年2型糖尿病(T2DM)的临床疗效。方法:选取2015年1月至2015年12月于我科就诊的80例老年T2DM患者作为研究对象。所有患者在常规基础上给予磷酸西格列汀联合阿卡波糖治疗。12周后,比较患者治疗前后血糖相关指标,并观察低血糖发生率。结果:12周后,患者空腹血糖、餐后2小时血糖、糖化血红蛋白A1C(Hb A1C)等血糖相关指标水平较治疗前明显降低(7.30±1.05 vs 9.25±1.48 mmol/L;8.06±1.27 vs 13.28±2.14mmol/L;7.15±0.96 vs 8.43±1.12%),比较都有统计学差异(P均<0.05)。治疗期间,低血糖发生率为5.0%。结论:磷酸西格列汀联合阿卡波糖在老年T2DM中应用效果良好,能够显著改善血糖指标,且低血糖发生率低,临床上值得应用。
Objective: To observe the clinical efficacy of sitagliptin phosphate and acarbose in the treatment of type 2 diabetes mellitus (T2DM). Methods: Eighty elderly patients with T2DM who were treated in our department from January 2015 to December 2015 were selected as the study subjects. All patients were treated with sitagliptin phosphate and acarbose on a routine basis. Twelve weeks later, the patients before and after treatment of blood glucose-related indicators, and observed the incidence of hypoglycemia. Results: After 12 weeks, the levels of fasting blood glucose, 2-hour postprandial blood glucose and HbA1c were significantly lower than those before treatment (7.30 ± 1.05 vs 9.25 ± 1.48 mmol / L; 8.06 ± 1.27 vs 13.28 ± 2.14mmol / L; 7.15 ± 0.96 vs 8.43 ± 1.12%, respectively) (all P <0.05). During treatment, the incidence of hypoglycemia was 5.0%. Conclusion: The combination of sitagliptin phosphate and acarbose has a good effect in elderly patients with T2DM, which can significantly improve the blood glucose level, and the incidence of hypoglycemia is low, which is worthy of clinical application.